It's important to consider your comfort with risk before diving in.

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...

The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking ...

The Andrew Hillman Grant for Biotech, established under the vision of Andrew Hillman, officially announces the opening of ...

Elon Musk's SpaceX may be igniting global headlines with the company's astronomical IPO, but biotech listings saw their own ...

Chinese drug makers are increasingly relying on overseas licensing deals to reach global markets amid growing geopolitical ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Tango Therapeutics stock soars after the biotech company announces initial data from its ongoing study on pancreatic cancer. An analyst calls the results ‘unprecedented.’ The medical device maker gave ...

In 2023, ReNAgade Therapeutics launched with $300 million to exploit an “all in one” technology solution for RNA-based therapies. That same year, Tome Biosciences emerged from stealth with $213 ...

Strong science, lower costs and growing capital networks are putting Spain and Portugal on the biotech investment map, even as structural bottlenecks persist, according to two investors.

Biotech firms develop drugs from living organisms; pharma from chemicals. Biotech products require a Biologics License Application for FDA approval. Investing focus should be on the long-term ...